Education
About Us
Working with TipRanks
Follow Us
Medicenna Therapeutics Corp (MDNAF)
OTHER OTC:MDNAF
MDNAF Stock Chart & Stats
$0.56
-$0.06(-5.24%)
At close: 4:00 PM EST
$0.56
-$0.06(-5.24%)
Day’s Range― - ―
52-Week Range$0.55 - $1.43
Previous CloseN/A
Volume34.40K
Average Volume (3M)42.08K
Market Cap
$38.37M
Enterprise Value$36.63M
Total Cash (Recent Filing)$15.75M
Total Debt (Recent Filing)$149.00K
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Jun 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding68,726,980
10 Day Avg. Volume52,191
30 Day Avg. Volume42,077
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)24.28
Price to Sales (P/S)0.00
P/FCF Ratio-7.75
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-872.23
Enterprise Value/Ebitda-1.73
Forecast
1Y Price Target
$2.94Price Target Upside424.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalAn improved response rate to 38% in a secondary immune checkpoint inhibitor–resistant cutaneous melanoma cohort suggests meaningful clinical activity that could enhance investor confidence.
Industry Partnering And Deal FlowRising pharma interest and recent high-value deals in anti-PD-1 bispecifics highlight growing commercial appetite, potentially attracting partners and licensing opportunities.
Platform And Pipeline PotentialOngoing promise of MDNA11 and advances in PD-1/IL-2 bispecific approaches point to differentiated therapeutic positioning and potential long-term pipeline value.
Bears Say
Insufficient Data ValidationLimited additional validation from recent data raises questions about reproducibility and increases the need for confirmatory studies before broader adoption.
Low Monotherapy EfficacyA monotherapy response rate of 8% signals limited single-agent effectiveness and may trigger investor skepticism about standalone therapeutic prospects.
Medicenna Therapeutics Corp News
MDNAF FAQ
What was Medicenna Therapeutics Corp’s price range in the past 12 months?
Medicenna Therapeutics Corp lowest stock price was $0.55 and its highest was $1.43 in the past 12 months.
What is Medicenna Therapeutics Corp’s market cap?
Medicenna Therapeutics Corp’s market cap is $38.37M.
When is Medicenna Therapeutics Corp’s upcoming earnings report date?
Medicenna Therapeutics Corp’s upcoming earnings report date is Jun 25, 2026 which is in 131 days.
How were Medicenna Therapeutics Corp’s earnings last quarter?
Medicenna Therapeutics Corp released its earnings results on Feb 13, 2026. The company reported -$0.037 earnings per share for the quarter, beating the consensus estimate of -$0.044 by $0.007.
Is Medicenna Therapeutics Corp overvalued?
According to Wall Street analysts Medicenna Therapeutics Corp’s price is currently Undervalued.
Does Medicenna Therapeutics Corp pay dividends?
Medicenna Therapeutics Corp does not currently pay dividends.
What is Medicenna Therapeutics Corp’s EPS estimate?
Medicenna Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicenna Therapeutics Corp have?
Medicenna Therapeutics Corp has 68,726,980 shares outstanding.
What happened to Medicenna Therapeutics Corp’s price movement after its last earnings report?
Medicenna Therapeutics Corp reported an EPS of -$0.037 in its last earnings report, beating expectations of -$0.044. Following the earnings report the stock price went down -2.806%.
Which hedge fund is a major shareholder of Medicenna Therapeutics Corp?
Currently, no hedge funds are holding shares in MDNAF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medicenna Therapeutics Corp Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.94 (424.65% Upside)
$2.94 (424.65% Upside)
Insider Transactions
Bought Shares
Worth C$161.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.89%
12-Months-Change
Fundamentals
Return on Equity
-69.80%
Trailing 12-Months
Asset Growth
-40.12%
Trailing 12-Months
Company Description
Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
MDNAF Stock 12 Month Forecast
Average Price Target
$2.94
▲(424.65% Upside)
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Covalon Technologies
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Ownership Overview
Options Prices
Currently, No data available
---